Building upon the success of single- and multi-exon skipping as a promising treatment paradigm for USH2A-associated RP, and given the repetitive protein domain architecture of ADGRV1, we hypothesized that the exon skipping strategy could be extended to ADGRV1-associated RP. Here, USH2A is linked to retinitis pigmentosa 1.